Pfizer/Pharmacia Merger Review: Firms Expect Second Request From FTC
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission's review of the Pfizer/Pharmacia merger should progress relatively smoothly because the same FTC reviewers worked with Pfizer on the Warner-Lambert deal, CEO Hank McKinnell told the Bear Stearns healthcare conference in New York Sept. 17
You may also be interested in...
Pfizer/Pharmacia OTC Motion Sickness Stronghold Could Make FTC Queasy
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
Bayer Rid Pediculicide Marketing Begins With Mousse Launch
Bayer Consumer Care's inaugural marketing efforts for the newly acquired Rid brand will focus on Maximum Strength Rid Mousse aerosolized foam lice treatment, which began shipping June 22.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC